Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 Jun;65(6):716-23.
doi: 10.1001/archneur.2008.65.6.nct70003. Epub 2008 Apr 14.

Serum urate as a predictor of clinical and radiographic progression in Parkinson disease

Michael A Schwarzschild  1 , Steven R Schwid, Kenneth Marek, Arthur Watts, Anthony E Lang, David Oakes, Ira Shoulson, Alberto Ascherio; Parkinson Study Group PRECEPT Investigators; Christopher Hyson, Emily Gorbold, Alice Rudolph, Karl Kieburtz, Stanley Fahn, Lisa Gauger, Christopher Goetz, John Seibyl, Misser Forrest, John Ondrasik
Collaborators, Affiliations
Randomized Controlled Trial

Serum urate as a predictor of clinical and radiographic progression in Parkinson disease

Michael A Schwarzschild et al. Arch Neurol. 2008 Jun.

Abstract

Objective: To determine whether concentration of serum urate, a purine metabolite and potent antioxidant that has been linked to a reduced risk of Parkinson disease (PD), predicts prognosis in PD.

Design: Prospective study.

Setting: The Parkinson Research Examination of CEP-1347 Trial (PRECEPT) study, which investigated the effects of a potential neuroprotectant on rates of PD progression, was conducted between April 2002 and August 2005 (average follow-up time 21.4 months).

Participants: Eight hundred four subjects with early PD enrolled in the PRECEPT study.

Main outcome measures: The primary study end point was progression to clinical disability sufficient to warrant dopaminergic therapy. Cox proportional hazards models were used to estimate the hazard ratio (HR) of reaching end point according to quintiles of baseline serum urate concentration, adjusting for sex, age, and other potential covariates. Change in striatal uptake of iodine I 123-labeled 2-beta-carbomethoxy-3-beta-(4-iodophenyl)tropane ([(123)I]beta-CIT), a marker for the presynaptic dopamine transporter, was assessed with linear regression for a subset of 399 subjects.

Results: The adjusted HR of reaching end point declined with increasing baseline concentrations of urate; subjects in the top quintile reached the end point at only half the rate of subjects in the bottom quintile (HR, 0.51; 95% confidence interval [CI], 0.37-0.72; P for trend < .001). This association was markedly stronger in men (HR, 0.39; 95% CI, 0.26-0.60; P for trend < .001) than in women (HR, 0.77; 95% CI, 0.39-1.50; P for trend = .33). The percentage of loss in striatal [(123)I]beta-CIT uptake also improved with increasing serum urate concentrations (overall P for trend = .002; men, P = .001; women, P = .43).

Conclusions: These findings identify serum urate as the first molecular factor directly linked to the progression of typical PD and suggest that targeting urate or its determinants could be an effective disease-modifying therapy in PD. Trial Registration clinicaltrials.gov Identifier: NCT00040404.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier estimates of the cumulative probability of reaching the end point by 24 months of follow-up, according to gender-specific quintiles of baseline serum urate. A. Men; B. Women. Log-rank tests: p=0.0011 in men, p=0.47 in women. At 24 months sample size was 46 in men and 21 in women.
Figure 1
Figure 1
Kaplan-Meier estimates of the cumulative probability of reaching the end point by 24 months of follow-up, according to gender-specific quintiles of baseline serum urate. A. Men; B. Women. Log-rank tests: p=0.0011 in men, p=0.47 in women. At 24 months sample size was 46 in men and 21 in women.
Figure 2
Figure 2
Age-adjusted percent change in striatal [123I]β-CIT uptake according to overall and gender-specific quintiles of baseline serum urate. Median serum urate by quintiles (1 to 5) mg/dL: All: 3.8, 4.8, 5.5, 6.3, 7.5; Men: 4.4, 5.3, 6.0, 6.6, 7.8; Women: 3.1, 4.0, 4.5, 5.2, 6.6. * p < 0.05; ** p < 0.001 compared to corresponding quintile 1. P for linear trend: all, p= 0.002; men, p=0.0008; women, p=0.4.
See this image and copyright information in PMC

Comment in

Similar articles

  • Urate as a predictor of the rate of clinical decline in Parkinson disease.
    Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA; Parkinson Study Group DATATOP Investigators. Ascherio A, et al. Arch Neurol. 2009 Dec;66(12):1460-8. doi: 10.1001/archneurol.2009.247. Arch Neurol. 2009. PMID: 19822770 Free PMC article. Clinical Trial.
  • Serum urate and probability of dopaminergic deficit in early "Parkinson's disease".
    Schwarzschild MA, Marek K, Eberly S, Oakes D, Shoulson I, Jennings D, Seibyl J, Ascherio A; Parkinson Study Group PRECEPT Investigators. Schwarzschild MA, et al. Mov Disord. 2011 Aug 15;26(10):1864-8. doi: 10.1002/mds.23741. Epub 2011 Apr 29. Mov Disord. 2011. PMID: 21538532 Free PMC article.
  • Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial.
    Parkinson Study Group SURE-PD3 Investigators; Schwarzschild MA, Ascherio A, Casaceli C, Curhan GC, Fitzgerald R, Kamp C, Lungu C, Macklin EA, Marek K, Mozaffarian D, Oakes D, Rudolph A, Shoulson I, Videnovic A, Scott B, Gauger L, Aldred J, Bixby M, Ciccarello J, Gunzler SA, Henchcliffe C, Brodsky M, Keith K, Hauser RA, Goetz C, LeDoux MS, Hinson V, Kumar R, Espay AJ, Jimenez-Shahed J, Hunter C, Christine C, Daley A, Leehey M, de Marcaida JA, Friedman JH, Hung A, Bwala G, Litvan I, Simon DK, Simuni T, Poon C, Schiess MC, Chou K, Park A, Bhatti D, Peterson C, Criswell SR, Rosenthal L, Durphy J, Shill HA, Mehta SH, Ahmed A, Deik AF, Fang JY, Stover N, Zhang L, Dewey RB Jr, Gerald A, Boyd JT, Houston E, Suski V, Mosovsky S, Cloud L, Shah BB, Saint-Hilaire M, James R, Zauber SE, Reich S, Shprecher D, Pahwa R, Langhammer A, LaFaver K, LeWitt PA, Kaminski P, Goudreau J, Russell D, Houghton DJ, Laroche A, Thomas K, McGraw M, Mari Z, Serrano C, Blindauer K, Rabin M, Kurlan R, Morgan JC, Soileau M, Ainslie M, Bodis-Wollner I, Schneider RB, Waters C, Ratel AS, Beck CA, Bolger P, Callahan KF, Crotty GF, Klements D, Kostrzebski M, McMahon GM, Pothier L, Waikar SS, Lang A, Mestre T. Parkinson Study Group SURE-PD3 Investigators, et al. JAMA. 2021 Sep 14;326(10):926-939. doi: 10.1001/jama.2021.10207. JAMA. 2021. PMID: 34519802 Free PMC article. Clinical Trial.
  • Targeting urate to reduce oxidative stress in Parkinson disease.
    Crotty GF, Ascherio A, Schwarzschild MA. Crotty GF, et al. Exp Neurol. 2017 Dec;298(Pt B):210-224. doi: 10.1016/j.expneurol.2017.06.017. Epub 2017 Jun 13. Exp Neurol. 2017. PMID: 28622913 Free PMC article. Review.
  • Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S; Parkinson Study Group. Fahn S, et al. J Neurol. 2005 Oct;252 Suppl 4:IV37-IV42. doi: 10.1007/s00415-005-4008-5. J Neurol. 2005. PMID: 16222436 Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Oda M, Satta Y, Takenaka O, Takahata N. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol. 2002 May;19(5):640–653. - PubMed
    1. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A. 1981;78(11):6858–6862. - PMC - PubMed
    1. Jenner P. Oxidative stress in Parkinson’s disease. Ann Neurol. 2003;53 Suppl 3:S26–36. S36–28. - PubMed
    1. Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol. 2005 Oct;58(4):495–505. - PubMed
    1. Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM. Observations on serum uric acid and the risk of idiopathic Parkinson’s disease. Am J Epidemiol. 1996;144:480–484. - PubMed

Publication types

Associated data